Gilead Sciences, Inc. (GILD): Price and Financial Metrics

Gilead Sciences, Inc. (GILD)

Today's Latest Price: $60.21 USD

0.34 (-0.56%)

Updated Oct 21 6:55pm

Add GILD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

GILD Stock Summary

  • GILD has a higher market value than 97.42% of US stocks; more precisely, its current market capitalization is $75,486,744,318.
  • GILD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 307.83 -- higher than 88.8% of US-listed equities with positive expected earnings growth.
  • The volatility of Gilead Sciences Inc's share price is greater than that of only 3.91% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are ATVI, ADI, BIIB, AMAT, and RACE.
  • GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to

GILD Stock Price Chart Interactive Chart >

Price chart for GILD

GILD Price/Volume Stats

Current price $60.21 52-week high $85.97
Prev. close $60.55 52-week low $59.85
Day low $59.90 Volume 7,493,700
Day high $60.49 Avg. volume 14,659,546
50-day MA $64.65 Dividend yield 4.52%
200-day MA $71.15 Market Cap 75.49B

Gilead Sciences, Inc. (GILD) Company Bio

Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

GILD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$60.21$30.49 -50%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Gilead Sciences Inc. To summarize, we found that Gilead Sciences Inc ranked in the 30th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49.5%. As for the metrics that stood out in our discounted cash flow analysis of Gilead Sciences Inc, consider:

  • The company's compound free cash flow growth rate over the past 5.45 years comes in at -0.06%; that's greater than merely 17.6% of US stocks we're applying DCF forecasting to.
  • The company has produced more trailing twelve month cash flow than 93.51% of its sector Healthcare.
  • Gilead Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Gilead Sciences Inc? See CPIX, LMAT, HAPP, ILMN, and ZTS.

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

October 2020 Stock Considerations

New month... new stock considerations. I can't believe that October is already here... the final quarter of 2020. Seeing how fast time blows by simply reminds me to stay invested no matter how crazy the market seems to be. We have witnessed some pretty harsh declines this year only to...

Divhut on Seeking Alpha | October 3, 2020

Investors tackle new COVID-19 and stimulus wildcards with Trump hospitalized

The Latest: President Donald Trump is being treated with antiviral drug, Gilead's (GILD) remdesivir, at a U.S. military hospital, while campaign manager Bill Stepien and ex-White House adviser Kellyanne Conway have also tested positive.The president is also taking Regeneron's antibody cocktail as reported last night.Senators Thom Tillis from North Carolina and Mike...

Seeking Alpha | October 3, 2020

EMA committee probes possible kidney injury from Gilead's remdesivir | Health

The European drugs regulator said on Friday its safety committee was reviewing reports of acute kidney injury in some COVID-19 patients who had been given Gilead Sciences Inc's remdesivir. Kidney injury can be caused by COVID-19 as well as other factors such as diabetes, the EMA said in a statement.

Devdiscourse | October 2, 2020

T-Cell Therapy Market Explore By Size, Share, and Growth - CAGR of 14.9% Along With Top Key Players: Gilead Sciences, Inc., Sorrento Therapeutics, Fate Therapeutics Inc

Reports and Data has added a new report titled Global T-Cell Therapy Market to its ever-expanding repository, which aims to offers valuable insights into the T-Cell Therapy industry with regards to the market share, market size, market valuation, and regional

OpenPR | October 1, 2020

5 Top Stock Trades for Friday: PINS, CROX, STZ, CAG, GILD

Pinterest, Crocs, Gilead Sciences, Constellation Brands and ConAgra Foods were our top stock trades from Thursday.

InvestorPlace | October 1, 2020

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -5.03%
3-mo -17.38%
6-mo -22.93%
1-year -6.07%
3-year -16.64%
5-year -35.00%
YTD -4.66%
2019 7.88%
2018 -9.92%
2017 2.96%
2016 -27.59%
2015 8.63%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7607 seconds.